Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INVINCIBLE-3 trial of INT230-6 versus standard of care in advanced soft tissue sarcoma
2024-512423-36-00Phase 3Authorised
- Sponsor
- Intensity Therapeutics
- Start
- Sep 2024
- Modality
- Small Molecules
- Countries
- 8
01
Overview
Phase 3, randomised, open-label trial in soft tissue sarcoma (STS), leiomyosarcoma (LMS), Liposarcoma and 1 more comparing INT230-6 with Standard of care (2 arms). Primary endpoint: Overall survival. Planned start Sep 2024; status: authorised.
02
Drugs
INT230-6
03
Conditions
soft tissue sarcoma (STS)leiomyosarcoma (LMS)LiposarcomaMalignant Fibrous Histiocytoma (MFH)
Beyond the preview
Go deeper on 2024-512423-36-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512423-36-00.